Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMark R. DowlingSIShafqat InamJLJian Li

Discussion

Loading...

Member takes

Overview

Real-world data reveals scoring model improves toxicity and survival outcomes in patients with large B-cell lymphoma treated with CAR-T.

Key Points

  • This research evaluates a scoring system for predicting responses and toxicities in CAR-T therapy for large B-cell lymphoma.
  • Analyzed data from adult patients with relapsed/refractory large B-cell lymphoma eligible for CAR-T.
  • Used Cox proportional hazards models to identify risk factors impacting outcomes at apheresis and pre-lymphodepletion.
  • Established predictive scoring systems based on identified risk factors.
  • 632 patients with a median age of 66 were included in the study.
  • Treatment with CAR-T showed overall response rates of 73% for tisa-cel and 85% for axi-cel.
  • 12-month progression-free survival rates were 34% (tisa-cel) and 47% (axi-cel), with variances seen with risk factors.

Cite This Study

Dowling et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d74chttps://doi.org/10.1182/blood-2025-399
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement2025
  2. 2Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience2025
  3. 3Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.2025
  4. 4Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study2026 · 5 citations
  5. 5Data from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas2024